Sentinel lymph node biopsy is an important procedure for staging of cancers like breast cancer and melanoma. It helps determine whether cancer has spread from the primary site to lymph nodes. This minimally invasive diagnostic technique provides critical information to guide treatment decisions for patients. During the procedure, a radioactive tracer or blue dye is injected near the cancer site which travels to the first draining lymph node, known as the sentinel lymph node. Surgeons then remove this lymph node to check for the presence of cancer cells. If sentinel lymph node is cancer-free, it is unlikely that the cancer has spread to other lymph nodes. This reduces unnecessary additional surgery for lymph node dissection.
Market Dynamics:
Market drivers such as rising cancer incidence globally and growing preference for minimally invasive techniques are fueling the demand for sentinel lymph node biopsy. Early and accurate staging of cancers is critical for determining personalized treatment options. Sentinel lymph node biopsy addresses this need in a less invasive manner compared to full lymph node dissection surgery. However, limitations of current radioactive tracers and short shelf life of kits pose a challenge. Also, availability of alternative techniques for lymph node assessment restrains market growth. Going forward, the development of nanoparticle tracers with better detection ability and tracers customized for specific cancer types will expand opportunities.
Key Features of the Study:
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook